Shalowitz David I, Epstein Andrew J, Ko Emily M, Giuntoli Robert L
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States.
Division of General Internal Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States.
Gynecol Oncol. 2016 Jul;142(1):30-37. doi: 10.1016/j.ygyno.2016.04.026. Epub 2016 May 5.
To identify prevalence, correlates and survival implications of non-surgically managed epithelial ovarian cancer (EOC).
The National Cancer Database (NCDB) was queried for EOC cases between 2003 and 2011. Type of treatment, survival data, reasons for non-surgical treatment, clinicopathologic and process-based factors were collected. Logistic regression identified independent predictors of surgical treatment; Cox proportional hazards regression modeled association between time to death and receipt of surgery.
172,687 of 210,667 patients (82%) received surgical treatment for EOC. 95% of patients treated non-surgically had stage III, stage IV or unknown stage disease. The reason for non-surgical treatment was unclear in 80% of cases. Black race and uninsurance were significantly associated with non-surgical treatment. Median survival time was 57.4months (95% CI: 56.8-57.9) for surgery with or without systemic treatment compared to 11.9months (95% CI: 11.6-12.2) for systemic treatment alone and 1.4months (95% CI: 1.3-1.4) for no treatment. Relative to surgical treatment, the adjusted hazard ratio for death associated with systemic treatment alone was 1.9 (p<0.001); hazard ratio for untreated patients was 4.7 (p<0.001). Among 29,921 patients older than 75 with Stage III/IV disease, 21.5% received only systemic treatment; 22.8% were entirely untreated.
18% of EOC patients in the NCDB did not receive surgical treatment. These patients experienced significantly worsened survival. Prospective investigation is needed to determine how often apparent deviation from best-practices guidelines is clinically appropriate. Non-surgically treated patients may be at risk for poor access to gynecologic oncology care and deserve further study.
确定非手术治疗的上皮性卵巢癌(EOC)的患病率、相关因素及生存影响。
查询国家癌症数据库(NCDB)中2003年至2011年的EOC病例。收集治疗类型、生存数据、非手术治疗原因、临床病理及基于过程的因素。逻辑回归确定手术治疗的独立预测因素;Cox比例风险回归模拟死亡时间与手术接受情况之间的关联。
210,667例患者中有172,687例(82%)接受了EOC手术治疗。95%接受非手术治疗的患者患有III期、IV期或分期不明的疾病。80%的病例非手术治疗原因不明。黑人种族和未参保与非手术治疗显著相关。接受手术联合或不联合全身治疗的患者中位生存时间为57.4个月(95%CI:56.8 - 57.9),而单纯全身治疗患者为11.9个月(95%CI:11.6 - 12.2),未治疗患者为1.4个月(95%CI:1.3 - 1.4)。相对于手术治疗,单纯全身治疗相关死亡的调整后风险比为1.9(p<0.001);未治疗患者的风险比为4.7(p<0.001)。在29,921例年龄大于75岁的III/IV期疾病患者中,21.5%仅接受了全身治疗;22.8%完全未接受治疗。
NCDB中18%的EOC患者未接受手术治疗。这些患者的生存情况显著恶化。需要进行前瞻性研究以确定明显偏离最佳实践指南的情况在临床上合适的频率。非手术治疗的患者可能面临获得妇科肿瘤护理不佳的风险,值得进一步研究。